Quick Answer: Yes, GLP-1 receptor agonists effectively reduce visceral fat, as demonstrated by clinical trials using CT and MRI imaging showing significant decreases in visceral adipose tissue volume alongside improvements in waist circumference and cardiometabolic markers
If appetite suppression and weight loss continue at a satisfactory rate, the dose is adequate regardless of what the injectable equivalent might be
These are clinical research findings, not approved treatment claims, because retatrutide remains investigational and has not been approved for routine medical use [2], [3]
If you're ready to explore whether Zepbound is right for your situation, our physician-supervised telehealth platform provides the coordinated endocrine care you need get started
Regular Monitoring Scheduled check-ins to track progress, adjust dosing, manage side effects, and monitor blood sugar, kidney function, and overall health markers